The Role of Patient-reported Outcomes and Medication Adherence Assessment in Patient-focused Drug Development for Solid Organ Transplantation

Transplantation. 2021 May 1;105(5):941-944. doi: 10.1097/TP.0000000000003556.

Authors

Stephen R Karpen¹, Amanda Klein¹, Rita R Alloway², Renata Albrecht³, Ozlem Belen³, Michelle Campbell³, Paul Kluetz³, Lori M Minasian⁴, Sandra A Mitchell⁴, Inish O'Doherty¹, Elektra Papadopoulos³, Ruth Sapir-Pichhadze⁵, Nicole Spear¹, Teun van Gelder⁶, Ergun Velidedeoglu³, C Alex Page⁷, Matthew J Everly⁸

Affiliations

¹ Critical Path Institute, Tucson, AZ.
² Division of Nephrology, University of Cincinnati College of Medicine, Cincinnati, OH.
³ U.S. Food and Drug Administration, Silver Spring, MD.
⁴ National Institutes of Health, National Cancer Institute, Bethesda, MD.
⁵ McGill University, Montreal, QC, Canada.
⁶ Departments of Hospital Pharmacy and Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands.
⁷ University of Arizona College of Pharmacy, Tucson, AZ.
⁸ Cleverly Health, LLC, Los Angeles, CA.

PMID: 33901129
DOI: 10.1097/TP.0000000000003556

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Drug Development*
Graft Rejection / immunology
Graft Rejection / prevention & control*
Graft Survival / drug effects*
Humans
Immunosuppressive Agents / adverse effects
Immunosuppressive Agents / therapeutic use*
Medication Adherence*
Organ Transplantation* / adverse effects
Patient Reported Outcome Measures*
Time Factors
Treatment Outcome

Substances

Immunosuppressive Agents